'Promising' Status For Faron's Traumakine In UK Opens Possibilities For Early Access, Pricing Negotiations
Executive Summary
The UK regulator has granted a "promising designation" to Faron Pharmaceuticals' Traumakine acute respiratory distress syndrome treatment, which means the orphan drug may be made available to patients pre-approval under the early access scheme. The drug is currently in Phase III in the EU and Japan, with 420 moderate to severe ARDS patients expected to be treated.
You may also be interested in...
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.